Skip to main
CSTL
CSTL logo

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. has demonstrated remarkable growth in its TissueCypher test, with test volumes increasing 92% year-over-year and 23% quarter-over-quarter in 2Q25, indicative of strong market demand and effective sales force expansion. The company's strategic moves have led to improved gross margins for TissueCypher, achieving an impressive 77% in Q3, which underscores its operational efficiency and profitability. Additionally, the anticipated maturation of the gastrointestinal sales force in the latter half of 2025 further supports a positive growth trajectory for the company's diagnostics portfolio.

Bears say

Castle Biosciences Inc. faces a negative outlook due to concerns over the revenue generation potential of its primary tests, specifically the DecisionDx-Melanoma, in comparison to its TissueCypher product, with expectations that EV-to-estimated 2026/2027 revenue multiples for dermatology and DecisionDx-UM tests will be substantially lower. Additionally, management's acknowledgment of significant clinician unawareness regarding the tests indicates a substantial barrier to market penetration, impacting revenue growth prospects. Despite indications that the stock may appear undervalued based on conservative estimates, these fundamentals suggest a challenging environment for sustained financial performance.

CSTL has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.